BioAtla Bags Major New Backer
Tuesday, January 12, 2016 5:40:00 AM PDT | VentureDeal
   San Diego, California  --  Biotechnology company BioAtla has received $45 million in new venture capital debt and equity.

BioAtla is developing antibody therapeutics using Conditionally Active Biologics (CABs).

The company recently entered into a strategic license and option agreement with pharmaceutical giant Pfizer.

Global BIO Impact Fund made the investment.

The fund will "share in the risks and the potential returns of BioAtla's first four CAB candidates."